The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

NCT07185269 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: 626
DRUG: 626
DRUG: Placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.